tailieunhanh - báo cáo khoa học: "Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case report"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case report | Syrios et al. Journal of Medical Case Reports 2010 4 401 http content 4 1 401 jAl JOURNALOF medical ÌỤr case REPORTS CASE REPORT Open Access Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab Herceptin maintenance therapy in a woman a case report John Syrios Anna Dokou Nicolas Tsavaris Abstract Introduction This case report and short review discusses how long trastuzumab should be continued in metastatic breast cancer the safety issues in case of pregnancy and the risk of relapse with trastuzumab cessation. Case presentation We present the case of a 34-year-old Caucasian woman with human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver who achieved prolonged complete remission within six months of receiving trastuzumab Herceptin in combination with vinorelbine and gemcitabine. The patient remains in complete remission seven years later and continues to receive trastuzumab as maintenance therapy. Conclusion Trastuzumab-based therapies have greatly improved the survival rates of patients with human epidermal growth factor receptor 2- positive metastatic breast cancer. Despite such improvements the safety of trastuzumab administration during pregnancy is yet to be defined. Introduction The development of trastuzumab Herceptin a humanized human epidermal growth factor receptor 2 HER2 monoclonal antibody has changed the natural history of HER2-positive breast cancer providing superior survival benefits in combination or as monotherapy compared with nontrastuzumab-based therapy 1 2 . However HER2-positive metastatic breast cancer MBC is an aggressive disease and despite these advances the majority of patients treated with trastuzumab-based regimens progress within one year with only very few patients experiencing prolonged remission 3 . The case report presented here describes a woman who underwent a mastectomy for

TÀI LIỆU LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.